Evidence map›Paper›PMID 42820012›Full record

ArticleJACS Au2026

Halogen-Guided Reconstructive Transformation of Hydroxycoumarin to Coumaranone.

Yusuke Yoto, Yusei Matsumoto, Kotaro Kikushima, Mihoyo Fujitake, Hideyasu China, Toshifumi Dohi

Abstract read
In one paragraph

Article in JACS Au, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yusuke YotoCollege of Pharmaceutical Sciences, Ritsumeikan University, 1-1-1, Nojihigashi, Kusatsu, Shiga 525-0058, Japan.
Yusei MatsumotoCollege of Pharmaceutical Sciences, Ritsumeikan University, 1-1-1, Nojihigashi, Kusatsu, Shiga 525-0058, Japan.
Kotaro KikushimaCollege of Pharmaceutical Sciences, Ritsumeikan University, 1-1-1, Nojihigashi, Kusatsu, Shiga 525-0058, Japan.ORCID https://orcid.org/0000-0003-3009-0222
Mihoyo FujitakeCenter for Pharmaceutical Research and Development, Osaka Medical and Pharmaceutical University, 4-20-1, Nasahara, Takatsuki, Osaka 569-1094, Japan.
Hideyasu ChinaFaculty of Pharmaceutical Sciences, Doshisha Women's College of Liberal Arts, 97-1, Minamihokotate, Kodo, Kyotanabe, Kyoto 610-0395, Japan.
Toshifumi DohiCollege of Pharmaceutical Sciences, Ritsumeikan University, 1-1-1, Nojihigashi, Kusatsu, Shiga 525-0058, Japan.ORCID https://orcid.org/0000-0002-2812-9581

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Halogenation-driven skeletal transformations play an important role in the biosynthesis of natural products, where halogenation can promote C-C bond cleavage under mild conditions. Drawing inspiration from these biosynthetic processes, the halogenative skeletal reconstruction of hydroxycoumarins is reported, which unexpectedly facilitates carbonyl deletion to yield valuable heterocyclic scaffolds. Notably, cleavage of both the C-C and C-O bonds occurs under the mildest nonenzymatic conditions reported to date (low reaction temperature and near-neutral reaction media), while also demonstrating broad substrate scope. This transformation converts readily accessible hydroxycoumarins into biologically relevant coumaranone scaffolds via a halogen-identity-dependent decarbonylative reconstruction. This work establishes halogenation-enabled carbonyl deletion as a useful strategy for skeletal transformation and provides an efficient approach to molecular scaffold editing relevant to medicinal chemistry.

Indexed as

carbonyl deletioncoumaranone synthesisdecarbonylative reconstructiondual C–C and C–O bond scissionhalogenase-inspired chemistrymildest bond cleavagenear-neutral conditions

Identifiers

PMID42820012
PMCPMC13625728

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.